Sonnet BioTherapeutics

PURRPhase 2

Sonnet BioTherapeutics leverages its modular FHAB technology to create a pipeline of cytokine-derived therapies aimed at improving the therapeutic window and efficacy of immunomodulatory drugs in oncology. The company's lead program is in Phase 1 development with a combination study involving Roche's atezolizumab, and it has established collaborations for investigator-initiated trials. Following a recent business combination with Hyperliquid Strategies Inc., the company now trades on the Nasdaq Capital Market under the ticker 'PURR', positioning it to advance its clinical-stage pipeline.

Market Cap

$644.6M

Focus

Biologics

PURR · Stock Price

USD 5.20+1.30 (+33.33%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Fully Human Albumin-Binding (FHAB) platform using a single-chain antibody fragment (scFv) that binds to human serum albumin to deliver therapeutic payloads (e.g., cytokines) directly to tumors, enhancing pharmacokinetics and targeting.

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
SON-080	Chemotherapy-induced Peripheral Neuropathy (CIPN)	Phase 1/2
SON-1010	Advanced Solid Tumor	Phase 1/2
SON-1010 (IL12-FHAB)	Healthy Adult	Phase 1
SON-1010	Advanced Solid Tumor	Phase 1

Funding History

Total raised: $50M

IPO$25MUndisclosedOct 15, 2020

Series A$20MUndisclosedFeb 15, 2019

Seed$5MUndisclosedMay 15, 2017

Opportunities

The modular FHAB platform offers the opportunity to rapidly generate a broad pipeline of targeted cytokine therapies for multiple cancer indications.

The bifunctional candidate SON-1210 represents a novel approach.

The partnership with Roche provides validation and a path for combination therapy in a high-need area (PROC).

Risk Factors

Extremely high risk due to early-stage clinical pipeline, unproven technology platform, and a novel, complex corporate structure following the merger with a digital asset company.

Heavy competition in immuno-oncology and reliance on future capital raises or partnerships to fund development.

Competitive Landscape

Competes with other companies developing engineered cytokines (e.g., Alkermes, Immunogen) and albumin-targeting drug delivery platforms. Differentiation is based on the specific fully human FHAB scFv construct, modular design, and focus on improving the therapeutic window of potent cytokines like IL-12 and IL-15.

Publications

Patents

Pipeline